


wilate®

von Willebrand
Factor/Coagulation
Factor VIII Complex
(Human)

KERRI BORGESSE

Switched from Humate-P®
to wilate®



At 6 months of age, Kerri Borgesse's mother noticed that her infant daughter was bruising just from sitting in a highchair. She alerted their pediatrician, who referred them to a hematologist. Shortly after, Kerri was diagnosed with severe, type 3 von Willebrand disease (VWD).

Despite her diagnosis, Kerri describes her childhood as normal—active, fun, and with few limitations. She credits her parents for doing a great job of making things as normal as possible. “I have an older and a younger sister (both are asymptomatic carriers), and I never felt like I was that different. I wore a helmet and knee pads for biking and sports, but for the most part I felt normal, and I think my parents did a really good job of making it that way.”

- Throughout her childhood, Kerri was mostly prescribed Humate-P, and sometimes Alphanate®. Her bleeding was treated as needed (on-demand) for joint bleeds, nosebleeds, and sports injuries.
- With adolescence and adulthood, Kerri experienced heavy and prolonged menstrual bleeding, very common in women with VWD, and was treated more frequently and with higher doses to manage her symptoms.
- Last year (at age 25), Kerri switched to wilate—and with that, a much lower dose to manage her bleeds.

Kerri Today | Living and Thriving with Type 3 VWD

Kerri takes great pride as a pediatric nurse, an avid runner, and a patient advocate. She has been managing her type 3 VWD with wilate for more than 6 months, and with great success. “I just feel a difference on wilate. My joints feel better. If I have an active bleed, it works really well.”

Kerri recognizes that women, especially those in their teens, face challenges when it comes to getting information about menstrual bleeding in VWD. “It can be hard to manage. It’s a trial and error process. It’s definitely something we need more people talking about and raising awareness.” To that end, she recommends that everyone living with severe VWD educate themselves about their specific symptoms—and then take control of their therapy. Kerri also recommends that people with severe VWD join the Severe von Willebrand’s group on Facebook, which is dedicated to those living with severe type 3 VWD.

“I was using so much Humate-P to control my bleeding. It was one of the reasons I wanted to switch. Today, I’m using much less with wilate.”

Indications and Usage

wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in children and adults with von Willebrand disease for on-demand treatment and control of bleeding episodes, and for perioperative management of bleeding. wilate is also indicated in adolescents and adults with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes, and for on-demand treatment and control of bleeding episodes.

Please see enclosed full Prescribing Information. Please see other side for Important Safety Information.



von Willebrand
Factor/Coagulation
Factor VIII Complex
(Human)

Low Recommended Dosing for All Types of VWD

wilate Offers Low Recommended Loading and Maintenance Dosing
for Both Minor and Major Bleeding^{1*}

Type of Hemorrhages	Loading Dosage (IU VWF:RCo/kg BW)	Maintenance Dosage (IU VWF:RCo/kg BW)	Therapeutic Goal
Minor hemorrhages	20-40 IU/kg	20-30 IU/kg every 12 to 24 hours ^a	VWF:RCo and FVIII activity trough levels of >30%
Major hemorrhages	40-60 IU/kg	20-40 IU/kg every 12 to 24 hours ^a	VWF:RCo and FVIII activity trough levels of >50%

BW = body weight.

^{*}Based on the Recommended Dosing Guide for wilate[®]. See Dosage and Administration, section 2.1 of Full Prescribing Information.

^aThis may need to be continued for up to 3 days for minor hemorrhages and 5 to 7 days for major hemorrhages.

The Power of Balance for the Treatment of VWD

- A balanced 1:1 formulation of VWF/FVIII—similar to naturally occurring VWF and FVIII¹
- Effective control of major and minor bleeding²
- Dual viral inactivation steps—solvent/detergent and dry heat treatments¹
- Simple and convenient to use

Important Safety Information

wilate[®] is contraindicated in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions to human plasma-derived products, any ingredient in the formulation, or components of the container. wilate is made from human plasma and carries the risk of transmitting infectious agents.

The most serious adverse reactions to treatment with wilate in patients with VWD were hypersensitivity reactions. The most common adverse reactions (≥1%) in patients with VWD were hypersensitivity reactions, urticaria, and dizziness. The most common adverse reaction to treatment with wilate in patients with hemophilia A was pyrexia. Seroconversions for antibodies to parvovirus B19 not accompanied by clinical signs of disease have been observed. Monitor plasma levels of FVIII activity to avoid sustained excessive FVIII levels, which may increase the risk of thromboembolic events. Development of neutralizing antibodies to FVIII and to VWF, especially in VWD type 3 patients, may occur.

Please see enclosed full Prescribing Information.

References: 1. wilate[®], von Willebrand Factor/Coagulation Factor VIII Complex (Human) full prescribing information. Hoboken, NJ: Octapharma; rev 2019.
2. Berntorp E, et al. Haemophilia. 2009;15:122-130.

